-
-
-
-
-
-
-
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in
-
-
-
-
-
-
-
Innoviva (INVA) Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam
-
-
-
-
-
-
-
Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, Presents Efficacy and Safety Data from Landmark Phase 3 ATTACK Trial at IDWEEK 2022
-
-
-
-
-
-
-
Innoviva Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
-
-
-
-
-
-
-
Innoviva to Acquire La Jolla Pharmaceutical Company
-
-
-
-
-
-
-
Innoviva to Acquire Entasis Therapeutics
-
-
-
-
-
-
-
Innoviva Reports Fourth Quarter 2020 Financial Results
-
1,154,948 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

